Accelerō® Bioanalytics, a Berlin based contract research organization (CRO) specialized in the development and validation of custom ligand binding assays, announced today that the company´s instrumentation was supplemented by Biotek´s state-of-the-art Synergy 2 multimode plate reader for ultra-sensitive fluorescence, luminescence, and absorbance detection.
The need for assay techniques which allow for the bioanalysis of very low sample volumes (1-3 µl per measurement) is the moving spirit for our DMPK assay development activities.
Biotek´s Synergy 2 reader meets this requirement: it supports 6 to 1536 well assay formats. Though basic 96-well assays are part of Accelero Bioanalytics´ everyday work, 384-well assay formats are increasingly requested.
Analyte concentrations in complex sample extracts or crude lysates can be normalized to total RNA, DNA, or protein contents by Biotek´s Take3 Trio sample measurement tool, which substitutes commonly used UV-Vis Spectrophotometers. Only 2 µl sample volume are ideal for sensitive and accurate detection, with the enjoyable site effect that all data are generated by an 21 CFR part 11 compliant plate reader.
The Synergy 2 is also ideal for quantitative assays based on FRET technology. Basically, a ligand (e.g. like a peptide drug) is captured by two different acceptor molecules (e.g. like monoclonal antibodies) in a liquid phase assay format. The first antibody is tagged with a fluorescence donor molecule, the other one is labelled with an fluorescence acceptor. Upon binding to the ligand, both fluorescence tags are brought to close proximity to each other, which enables an inter-molecular energy transfer from the (excited) donor to the acceptor.
There are different FRET assay technologies available, all of them are supported by Biotek´s Synergy 2 Multimode Plate Reader, e.g. like:
Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET) like Invitrogen´s LanthaScreen™ Technology (with involving the donor/acceptor pairs Terbium/Fluorescein or Europium/AlexaFluor 647). The Synergy 2 reader is certified for LanthaScreen assays.
Amplified Luminescent Proximity Homogeneous Assay (Alpha), like AlphaScreen® and AlphaLISA® assays, which utilize beads bearing the donor and acceptors for FRET. AlphaLISA beads emit a strong peak at 615 nm, and are optimized for serum and plasma samples. Main advantages over conventional absorbance-based ELISAs are:
- Numerous assays are available for the quantification of the most commonly requested targets (biomarkers, cytokines, etc), all of them in a …
- Convenient and cost-effective 384 well format, which results in …
- The consumption of quite low sample volumes;
- Additionally, AlphaLISA® assays are no-wash assays, as the ligand is directly quantified in the liquid phase.
Accelero Bioanalytics is proud to offer all of these assays under the Good Laboratory Practice regulations. The service also includes custom 384-well AlphaLISA assay development and validation according to related guidelines.
Accelero Bioanalytics is an international contract research organization for the development and validation of DMPK ligand binding assays. The company started its operative business in September 2011, and is on its way to continuously expand both services and assay portfolio.
Our team focuses on custom projects in the field of investigational new drugs based on nucleic acid chemistry or peptide/protein composition. Another field of interest is the development of an own assay pipeline to encounter the increasing need for sensitive quantification assays, with simultaneously decreasing sample volumes being available for the assays.
Additional informations or web recources:
Accelero® is a registered trademark owned by Accelerō Bioanalytics, Berlin.
AlphaScreen®, AlphaLISA® are registered trademarks of Perkin Elmer Inc.
LanthaScreen™, Adapta® are registered trademarks of Invitrogen Inc.